Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trialResearch in context

Summary: Background: GST-HG171 is a potent, broad-spectrum, orally bioavailable small-molecule 3C like protease inhibitor that has demonstrated greater potency and efficacy compared to Nirmatrelvir in pre-clinical studies. We aimed to evaluate the efficacy and safety of orally administered GST-HG17...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hongzhou Lu, George Zhang, John Mao, Xiaochun Chen, Yangqing Zhan, Ling Lin, Tianxiang Zhang, Yanan Tang, Feng Lin, Feiyue Zhu, Yuanlong Lin, Yiming Zeng, Kaiyu Zhang, Wenfang Yuan, Zhenyu Liang, Ruilin Sun, Liya Huo, Peng Hu, Yihua Lin, Xibin Zhuang, Zhaohui Wei, Xia Chen, Wenhao Yan, Xiuping Yan, Lisa Mu, Zhuhua Lin, Xinyu Tu, Hongshan Tan, Fuhu Huang, Zhiqiang Hu, Hongming Li, Guoping Li, Haijun Fu, Zifeng Yang, Xinwen Chen, Fu-Sheng Wang, Nanshan Zhong
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-05-01
coleção:	EClinicalMedicine
Assuntos:	Anti SARS-CoV-2 drug COVID-19 RCT 3CL protease XBB variants
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589537024001615
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!